This week, Boehringer Ingelheim announced results from a 16-week phase 3 study that confirmed biosimilar adalimumab-adbm (to be sold as Cyltezo) was clinically equivalent to the reference product, Humira.
This week, Boehringer Ingelheim (BI) announced results from a 16-week phase 3 study that confirmed biosimilar adalimumab-adbm (to be marketed as Cyltezo) was clinically equivalent to the reference product, Humira.
The phase 3 study enrolled 318 patients between 18 and 78 years of age with moderate-to-severe chronic plaque psoriasis who were biologic naïve. Researchers randomized the patients to receive adalimumab-abdm or the reference product at 80 mg on day 1, 40 mg on day 7, and 40 mg every other week thereafter.
The primary endpoint, which was achieved, measured the number of patients who achieved a 75% reduction in the Psoriasis Area and Severity Index (PASI) score at week 16. Additionally, the trial confirmed that there were no clinically meaningful differences in efficacy, safety, and immunogenicity in patients with moderate to severe plaque psoriasis.
Click here to read more about adalimumab biosimilars.
“The phase 3 study builds on recent evidence that demonstrates Cyltezo is equivalent to Humira for the treatment of moderately to severely active rheumatoid arthritis. these data reinforce the robust body of evidence that Boehringer Ingelheim is collecting to provide safe and effective treatment options that will contribute to the quality and sustainability of healthcare systems,” Key Tetzlaff, vice president and Medical Head of Therapeutic Area Biosimilars at BI, said in a statement.
Adalimumab-adbm, which was approved by the FDA last year, has yet to become commercially available in the United States as BI is currently engaged in patent litigation with reference product developer, AbbVie. Additionally, BI is currently conducting a clinical trial looking to demonstrate interchangeability between adalimumab-adbm and the reference product. This is the first interchangeability study of its kind in the United States, as the FDA has yet to finalize the guidelines around demonstrating and achieving an interchangeability designation. A final guidance is expected to be issued on or before May 2019.
Additional data from the 24-week study are expected to be presented next year.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.